Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is positioned favorably due to its advanced lead product candidate, oral (Z)-endoxifen, which is currently in Phase 2 clinical development for treating and preventing breast cancer, suggesting significant growth potential. The company's ongoing clinical trials are progressing well, and positive outcomes from these studies are expected to serve as strong catalysts for stock performance. Furthermore, the current valuation reflects a balance between the inherent high risks and notable growth prospects, indicating a compelling investment opportunity moving forward.

Bears say

Atossa Therapeutics reported a net loss of $10.9 million, translating to an earnings per share (EPS) of $(1.27), which was worse than both internal and consensus estimates of $(1.05). The company has historically faced significant financial losses, previously reporting a net loss of $8.7 million with an EPS of $(0.07), indicating a trend of widening deficits. Several risks further contribute to a negative outlook, including liquidity challenges, potential failures in demonstrating the safety and efficacy of product candidates, difficulties in obtaining regulatory approvals, and various external macroeconomic factors.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.